title: Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
abstract: OBJECTIVE
  To assess whether an epirubicin (EPI) -based chemotherapy plus hormonal regimen improves disease-free (DFS) in women older than 65 years, with node-positive, operable breast cancer (BC), relative to tamoxifen (TAM) alone.
  
  
  METHODS
  A total of 338 patients were randomly assigned after surgery to receive TAM 30 mg/d for 3 years (TAM, n = 164), or EPI 30 mg on days 1, 8, and 15 every 28 days for six cycles plus TAM 30 mg/d for 3 years (EPI-TAM, n = 174). In both arms, patients received radiotherapy, delivered after chemotherapy (CT) in the EPI-TAM group.
  
  
  RESULTS
  The 6-year DFS rates were 69.3% with TAM and 72.6% with EPI-TAM (P = .14). The multivariate analysis shows a relative risk of relapse of 1.93 (95% CI, 1.70 to 2.17) with TAM compared with EPI-TAM (P = .005). The 6-year OS, related to disease progression, was 79.1% and 79.8%, respectively (P = .41). Compliance with CT was good: 96.9% of patients received six cycles. The acute toxicity per patient was mild: grade 2 neutropenia in 5.9%, grade 2 anemia in 2.0%, grade 3 nausea or vomiting in 4.6%, and grade 3 alopecia in 7.2%. Five cases (in five patients) of decreased left ventricular ejection fraction occurred after CT: three after adjuvant CT, and two after anthracycline-based CT for relapse. One patient died as a result of dysrhythmia related to carcinomatous lymphangitis. No secondary leukemia occurred.
  
  
  CONCLUSIONS
  This study conducted in node-positive elderly patients demonstrates a significant contribution of a weekly EPI regimen in terms of DFS. Moreover, this regimen is safe for hematologic, nonhematologic, and cardiac toxicities.
authors.affiliation: Centre Georges-François Leclerc, Dijon, France. pfargeot@dijon.fnclcc.fr
authors.forename: Pierre
authors.initials: P
authors.lastname: Fargeot
authors.forename: Jacques
authors.initials: J
authors.lastname: Bonneterre
authors.forename: Henri
authors.initials: H
authors.lastname: Roché
authors.forename: Alain
authors.initials: A
authors.lastname: Lortholary
authors.forename: Mario
authors.initials: M
authors.lastname: Campone
authors.forename: Isabelle
authors.initials: I
authors.lastname: Van Praagh
authors.forename: Alain
authors.initials: A
authors.lastname: Monnier
authors.forename: Moïse
authors.initials: M
authors.lastname: Namer
authors.forename: Simon
authors.initials: S
authors.lastname: Schraub
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Barats
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Guastalla
authors.forename: Marie-Josèphe
authors.initials: MJ
authors.lastname: Goudier
authors.forename: Isabelle
authors.initials: I
authors.lastname: Chapelle-Marcillac
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001707:Biopsy, Needle; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008408:Mastectomy / Q000379:methods; D020714:Maximum Tolerated Dose; D008593:Menopause; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D018570:Risk Assessment; D015996:Survival Rate; D013629:Tamoxifen / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D013629:Tamoxifen; D015251:Epirubicin